InvestSMART

PYC Therapeutics Limited (ASX: PYC) - Announcements

Current share price for PYC : $1.645 0.015 (0.92%)+

ASX company news and announcements for PYC Therapeutics Limited (PYC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PYC Therapeutics Limited (PYC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PYC Therapeutics Limited (PYC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PYC Therapeutics Limited (PYC)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$1,620 Notification to Ineligible Retail Shareholders 9 Feb 2026 9:23AM $1.500 $1.645 risen by 9.67%
$1,620 Retail Offer Booklet 9 Feb 2026 9:21AM $1.500 $1.645 risen by 9.67%
$1,620 Investor Webinar 5 Feb 2026 12:09PM $1.495 $1.645 risen by 10.03%
$1,620 Completion of Placement and Institutional Entitlement Offer 4 Feb 2026 9:39AM $1.600 $1.645 risen by 2.81%
$1,620 Proposed issue of securities - PYC 2 Feb 2026 10:05AM $1.600 $1.645 risen by 2.81%
$1,620 Notice Under Section708AA(2)(f) 2 Feb 2026 9:40AM $1.600 $1.645 risen by 2.81%
$1,620 PYC Capital Raising Presentation 2 Feb 2026 9:40AM $1.600 $1.645 risen by 2.81%
$1,620 PYC Raising up to $653m to Deliver Human Efficacy Data 2 Feb 2026 9:40AM $1.600 $1.645 risen by 2.81%
$1,620 Trading Halt 2 Feb 2026 9:16AM $1.600 $1.645 risen by 2.81%
$1,620 Quarterly Activities/Appendix 4C Cash Flow Report 23 Jan 2026 8:50AM $1.665 $1.645 fallen by 1.20%
$1,620 Offer to Issue Director Options & Appendix 3Y 13 Jan 2026 6:28PM $1.625 $1.645 risen by 1.23%
$1,620 Update - Notification regarding unquoted securities - PYC 13 Jan 2026 5:01PM $1.625 $1.645 risen by 1.23%
$1,620 Corporate Presentation - JP Morgan Healthcare Conference 13 Jan 2026 9:18AM $1.640 $1.645 risen by 0.30%
$1,620 Offer to Issue Director Options and Appendix 3Y 9 Jan 2026 2:51PM $1.680 $1.645 fallen by 2.08%
$1,620 Notification regarding unquoted securities - PYC 6 Jan 2026 5:18PM $1.670 $1.645 fallen by 1.50%
$1,620 Issue of Employee Options 6 Jan 2026 5:11PM $1.670 $1.645 fallen by 1.50%
$1,620 Change of Director's Interest Notice - Peter Coleman 23 Dec 2025 8:01PM $1.560 $1.645 risen by 5.45%
$1,620 Notification regarding unquoted securities - PYC 23 Dec 2025 8:01PM $1.560 $1.645 risen by 5.45%
$1,620 Issue of Director Options 23 Dec 2025 7:43PM $1.560 $1.645 risen by 5.45%
$1,620 PKD Clinical Trial - Safety Outcomes in Part A 19 Dec 2025 9:27AM $1.485 $1.645 risen by 10.77%
$1,620 Change of Director's Interest Notice 26 Nov 2025 7:22PM $1.485 $1.645 risen by 10.77%
$1,620 PKD Clinical Trial - Approval to Escalate Dosing 24 Nov 2025 8:21AM $1.380 $1.645 risen by 19.20%
$1,620 Appendix 3X and 3Z 18 Nov 2025 7:12PM $1.260 $1.645 risen by 30.56%
$1,620 Results of Annual General Meeting 18 Nov 2025 3:40PM $1.280 $1.645 risen by 28.52%
$1,620 Becoming a substantial holder 18 Nov 2025 9:45AM $1.300 $1.645 risen by 26.54%

76 - 100 of 961 results

Page 4 of 39

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.